Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 12/20 | 0.46 |
| ▸ | MET | P08581 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461562 | 0.87 | BRAF (0.49) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL2314091 | 0.86 | KDR (0.47) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL2314489 | 0.84 | KDR (0.43) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL2314497 | 0.84 | KDR (0.43) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL29837320 | 0.84 | KDR (0.49) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL29837321 | 0.84 | KDR (0.49) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL2315935 | 0.84 | KDR (0.49) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL2931209 | 0.82 | BRAF (0.44) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL3561767 | 0.81 | MAPK14 (0.61) | KDRBRAFMETMAPK14FLT1 | |
| SCHEMBL2932022 | 0.81 | BRAF (0.71) | KDRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| WO-2021226547-A2 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-10100053-B2 | Process for the preparation of 8-(4-aminophenoxy)-4H-pyrido[2,3-b]pyrazin-3-one derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-10-16 | — | — | US | disclosed |
| EP-3074395-B1 | PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES | CANCER RESEARCH TECH LTD (GB) | 2018-08-22 | — | — | EP | disclosed |
| US-20170298065-A1 | PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-10-19 | — | — | US | disclosed |
| US-9708317-B2 | Process for the preparation of 8-(4-aminophenoxy)-4H-pyrido[2,3-B]pyrazin-3-one derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-07-18 | — | — | US | disclosed |
| US-20160297814-A1 | PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES | OXY SCIENTIFIC LIMITED (GB) | 2016-10-13 | — | — | US | disclosed |
| EP-3074395-A1 | PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES | Cancer Research Technology Ltd (GB) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015075482-A1 | PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-05-28 | — | — | WO | disclosed |
| EP-2229391-A1 | PYRIDO[2,3-B]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009077766-A1 | PYRIDO[2,3-B]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100053-B2 | Process for the preparation of 8-(4-aminophenoxy)-4H-pyrido[2,3-b]pyrazin-3-one derivatives | PAM, PDXK, GRHPR | KDR 3183/4885PDGFRA 820/4885KIT 3448/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | KDR 4751/4885PDGFRA 4803/4885KIT 4277/4885 |
| US-20170298065-A1 | PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES | TDO2, HPD, PDXK | KDR 2592/4885PDGFRA 153/4885KIT 2713/4885 |
| US-20160297814-A1 | PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES | PAM, PDXK, GRHPR | KDR 3183/4885PDGFRA 820/4885KIT 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.